Abstract
It is well established that intestinal microbiota play an important role in the pathogenesis of inflammatory bowel disease (IBD), including ulcerative colitis and Crohns disease. Various methods of altering the composition of intestinal microbiota have been examined. Recent evidence suggests that the administration of select prebiotics, probiotics and synbiotics may improve the clinical outcome of patients with IBD. In addition, IBD patients are well known to carry a higher risk of developing colorectal cancer due to chronic inflammation. Therefore, probiotics and/or prebiotics may be appropriate treatments for prophylactic use due to their physiologic characteristics and lack of obvious toxicity. This review summarizes the current experimental and clinical knowledge about the role of intestinal microbiota in IBD, the prevention of carcinogenesis related to IBD, and its importance as a target for new forms of neutraceutical therapy.
Keywords: Butyrate, Crohn's disease, microbiota, prebiotics, probiotics, synbiotics, ulcerative colitis
Current Pharmaceutical Design
Title: The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Volume: 15 Issue: 18
Author(s): Osamu Kanauchi, Keiichi Mitsuyama and Akira Andoh
Affiliation:
Keywords: Butyrate, Crohn's disease, microbiota, prebiotics, probiotics, synbiotics, ulcerative colitis
Abstract: It is well established that intestinal microbiota play an important role in the pathogenesis of inflammatory bowel disease (IBD), including ulcerative colitis and Crohns disease. Various methods of altering the composition of intestinal microbiota have been examined. Recent evidence suggests that the administration of select prebiotics, probiotics and synbiotics may improve the clinical outcome of patients with IBD. In addition, IBD patients are well known to carry a higher risk of developing colorectal cancer due to chronic inflammation. Therefore, probiotics and/or prebiotics may be appropriate treatments for prophylactic use due to their physiologic characteristics and lack of obvious toxicity. This review summarizes the current experimental and clinical knowledge about the role of intestinal microbiota in IBD, the prevention of carcinogenesis related to IBD, and its importance as a target for new forms of neutraceutical therapy.
Export Options
About this article
Cite this article as:
Kanauchi Osamu, Mitsuyama Keiichi and Andoh Akira, The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease, Current Pharmaceutical Design 2009; 15 (18) . https://dx.doi.org/10.2174/138161209788489195
DOI https://dx.doi.org/10.2174/138161209788489195 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Evaluation of Anticancer Activity of 5-Ylidene-4- Aminothiazol-2(5H)-one Derivatives
Medicinal Chemistry Implication of Rho GTPases in Neurodegenerative Diseases
Current Drug Targets Exfoliated Epithelial Cells: A Non-Invasive way to Evaluate the Physiological State of Gastrointestinal Epithelium
Recent Patents on Biomedical Engineering (Discontinued) Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry Preparation, Characterization and <i>In Vitro</i> Biological Evaluation of Novel Curcumin Derivatives as Cytotoxic and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets Impact of Nutrients on the Functioning of Intestinal Goblet Cells: Health and Therapeutic Perspectives
Current Nutrition & Food Science Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Prediction of Linear B-Cell Epitopes with mRMR Feature Selection and Analysis
Current Bioinformatics The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Protein & Peptide Letters Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets